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Introduction: Elevated expression of erbB3 rendered erbB2-overexpressing breast cancer cells resistant to paclitaxel
via PI-3 K/Akt-dependent upregulation of Survivin. It is unclear whether an erbB3-targeted therapy may abrogate
erbB2-mediated paclitaxel resistance in breast cancer. Here, we study the antitumor activity of an anti-erbB3 anti-
body MM-121/SAR256212 in combination with paclitaxel against erbB2-overexpressing breast cancer.
Methods: Cell growth assays were used to determine cell viability. Cells undergoing apoptosis were quantified by a
specific apoptotic ELISA. Western blot analyses were performed to assess the protein expression and activation.
Lentiviral vector containing shRNA was used to specifically knockdown Survivin. Tumor xenografts were established
by inoculation of BT474-HR20 cells into nude mice. The tumor-bearing mice were treated with paclitaxel and/or
MM-121/SAR256212 to determine whether the antibody (Ab) enhances paclitaxel’s antitumor activity.
Immunohistochemistry was carried out to study the combinatorial effects on tumor cell proliferation and
induction of apoptosis in vivo.
Results: MM-121 significantly facilitated paclitaxel-mediated anti-proliferative/anti-survival effects on SKBR3 cells
transfected with a control vector or erbB3 cDNA. It specifically downregulated Survivin associated with inactivation of
erbB2, erbB3, and Akt. MM-121 enhances paclitaxel-induced poly(ADP-ribose) polymerase (PARP) cleavage, activation of
caspase-8 and −3, and apoptosis in both paclitaxel-sensitive and -resistant cells. Specific knockdown of Survivin in the
trastuzumab-resistant BT474-HR20 cells dramatically enhanced paclitaxel-induced apoptosis, suggesting that increased
Survivin caused a cross-resistance to paclitaxel. Furthermore, the studies using a tumor xenograft model-established
from BT474-HR20 cells revealed that either MM-121 (10 mg/kg) or low-dose (7.5 mg/kg) paclitaxel had no effect on
tumor growth, their combinations significantly inhibited tumor growth in vivo. Immunohistochemical analysis showed
that the combinations of MM-121 and paclitaxel significantly reduced the cells with positive staining for Ki-67 and
Survivin, and increased the cells with cleaved caspase-3.
Conclusions: The combinations of MM-121 and paclitaxel not only inhibit tumor cell proliferation, but also promote
erbB2-overexpressing breast cancer cells to undergo apoptosis via downregulation of Survivin in vitro and in vivo,
suggesting that inactivation of erbB3 with MM-121 enhances paclitaxel-mediated antitumor activity against erbB2-
overexpressing breast cancers. Our data supports further exploration of the combinatorial regimens consisting of MM-121
and paclitaxel in breast cancer patients with erbB2-overexpressing tumors, particularly those resistant to paclitaxel.* Correspondence: bolin.liu@ucdenver.edu
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The erbB receptor tyrosine kinase (RTK) family, includ-
ing the epidermal growth factor receptor (EGFR), erbB2
(or Her2/neu), erbB3, and erbB4, is arguably the most
important receptor family in the context of development
and tumorigenesis [1,2]. Amplification and/or overex-
pression of erbB2 occur in approximately 25 to 30% of
invasive breast cancers and are significantly associated
with a worse prognosis in breast cancer patients [3,4].
Numerous studies indicate that increased treatment re-
sistance and enhanced metastatic potential are two of
the major mechanisms by which erbB2 contributes to
breast carcinogenesis [5,6]. Most metastatic breast can-
cers show expression for either EGFR or erbB2, and less
often for both [7]. In contrast, co-expression of erbB2
and erbB3 frequently occurs in breast cancers [8] and
breast cancer cell lines [9]. The erbB3 receptor is unique
among the four erbB family members. Unlike EGFR,
erbB2, and erbB4, it lacks kinase activity [10,11] or pos-
sesses weak kinase activity [12]. However, erbB3 has
been shown to serve as a critical co-receptor of erbB2,
and its expression is a rate-limiting factor for erbB2-
mediated breast cancer cell survival and proliferation
[13,14]. We and others have also observed an elevated
expression of the endogenous mouse erbB3 in the mam-
mary tumors derived from erbB2/neu-transgenic mice
[15,16]; and the increased erbB3 forms physical and func-
tional interactions with the transgene-encoded erbB2 to
promote mammary tumorigenesis [15]. In fact, the erbB2/
erbB3 heterodimer has been identified as the most potent
form of all erbB receptor complexes to activate the onco-
genic signaling, such as PI-3 K/protein kinase B (Akt),
mitogen-activated protein kinase kinase (MEK)/mitogen-
activated protein kinase (MAPK), and/or janus kinase
(Jak)/signal transducer and activator of transcription (Stat)
pathways, and/or Src kinase, in breast cancers [17-19].
Mechanistic studies implicate the function of erbB3 as
a major cause of treatment failure in human cancers
[20]. Therapeutic targeting of erbB3 is being investi-
gated. Currently, no erbB3-targeted therapy has been ap-
proved for cancer treatment. Several erbB3 blocking
antibodies (Abs) that prevent ligand-induced activation of
erbB3, such as MM-121/SAR256212 (which is being co-
developed by Merrimack Pharmaceuticals, Cambridge,
MA, USA and Sanofi, Cambridge, MA, USA), MM-111
(Merrimack Pharmaceuticals) and U3-1287/AMG 888
(Amgen Inc., Thousand Oaks, CA, USA) are actively
under preclinical and clinical studies [21] and show sig-
nificant antitumor activity in preclinical studies [22-25].
MM-121 is a fully humanized anti-erbB3 monoclonal
IgG2 Ab. It inhibits ligand-induced activation of erbB3,
and exerts antitumor activity in human cancer models
[23,24]. Nonetheless, MM-121’s therapeutic potential
against erbB2-overexpressing breast cancers that areresistant to chemotherapy and/or the erbB2-targeted ther-
apy has not been explored.
We have reported that activation of erbB3, mainly
through PI-3 K/Akt signaling, plays a critical role in
erbB2-mediated therapeutic resistance to tamoxifen [26]
and paclitaxel [27]. The erbB3 receptor also interacts
with both erbB2 and the insulin-like growth factor-1 re-
ceptor (IGF-1R) to form a heterotrimeric complex,
which activates the PI-3 K/Akt signaling and Src kinase
and subsequently results in resistance to erbB2-targeted
therapy, trastuzumab (Herceptin) [28]. Since activation
of the PI-3 K/Akt signaling is the major determinant of
treatment resistance [29], we investigated, in vitro and
in vivo, whether the anti-erbB3 Ab MM-121 would be able
to overcome resistance and enhance the efficacy of chemo-
therapy or trastuzumab against erbB2-overexpressing breast
cancer models via inhibition of the erbB3/PI-3 K/Akt
signaling. In the current report, we sought to determine
the antitumor activity of MM-121 in combination with
paclitaxel against erbB2-overexpressing breast cancer
using both in vitro and in vivo models. Our previous
studies indicated that elevated expression of erbB3 led
to paclitaxel resistance in erbB2-overexpressing breast
cancer cells via PI-3 K/Akt signaling-dependent upreg-
ulation of Survivin [27]. Thus, we have focused on
studying whether inactivation of erbB3 signaling with
MM-121 may specifically downregulate Survivin, and
subsequently re-sensitize the otherwise resistant breast
cancer cells to paclitaxel-mediated anti-proliferative/
anti-survival effects and apoptosis.
Methods
Reagents and antibodies
MM-121 was from Merrimack Pharmaceuticals, Inc.. Pacli-
taxel (Ben Venue Labs, Inc., Bedford, OH, USA) was ob-
tained from University of Colorado Hospital pharmacy.
Antibodies used for western blots were as follows: erbB2
(EMD Chemicals, Inc., Gibbstown, NJ, USA); erbB3 and P-
erbB2 (Tyr1248) (LabVision Corp., Fremont, CA, USA); P-
erbB3 (Tyr1289), caspase-8 (1C12), and caspase-3 (8G10),
P-MAPK (Thr202/Tyr204), MAPK, P-Akt (Ser473), Akt,
Survivin (6E4), Bcl-xL (Cell Signaling Technology, Inc.,
Beverly, MA, USA); Mcl-1 (clone 22) (BD Biosciences, San
Jose, CA, USA); poly(ADP-ribose) polymerase (PARP)
(BIOMOL Research Laboratories Inc., Plymouth Meeting,
PA, USA); and β-actin (Sigma-Aldrich Co., St. Louis, MO,
USA). All other reagents were purchased from Sigma un-
less otherwise specified.
Cells and cell culture
Human breast cancer cell lines MCF-7, MDA-MB-231,
SKBR3, and BT474 were obtained from the American Type
Culture Collection (Manassas, VA, USA). The SKBR3.B3.1
and SKBR3.B3.2 cells are two erbB3-transfected stable
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clone of SKBR3 cells [27]. The trastuzumab-resistant sub-
lines BT474-HR20 and SKBR3-pool2, derived from BT474
and SKBR3, respectively, were described previously [28].
All cell lines were maintained in DMEM/F-12 (1:1) (Sigma)
containing 10% FBS (Sigma), and cultured in a 37°C hu-
midified atmosphere containing 95% air and 5% CO2 and
split twice a week.
Cell proliferation assay
The CellTiter96 AQ nonradioactive cell proliferation kit
(Thermo Fisher Scientific Inc., Waltham, MA, USA) was
used to determine cell viability as previously described
[27,28,30]. Briefly, cells were plated onto 96-well plates
for 24 h, and then grown in either DMEM/F12 medium
with 0.5% FBS as control, or the same medium contain-
ing different concentrations of paclitaxel in the presence
or absence of MM-121, and then incubated for another
72 h. After reading all wells at 490 nm with a microplate
reader, the percentages of surviving cells from each group
relative to controls, defined as 100% survival, were deter-
mined by reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS).
Specific knockdown of Survivin expression with a
lentiviral system
Lentiviral production and specific knockdown of Survivin
expression with an shRNA strategy were carried out as de-
scribed previously [27]. In brief, the lentivirus-containing ei-
ther control shRNA or Survivin specific shRNA (Survivin-
S3 or Survivin-S5) were produced in 293 T cells following
the standard procedure. The virus in conditioned medium
were harvested, aliquoted, and stored in a −80°C freezer.
Prior to infection, the lentivirus-containing media were
thawed completely at room temperature, and mixed with
the same amount of fresh medium containing polybrene
(8 μg/ml). The culture media of the candidate breast cancer
cells were then replaced with the lentivirus-containing
media. After 24 h, the virus-infected cells were selected
with puromycin (1 μg/ml) for 48 h, and then subjected to
required experiments.
Quantification of apoptosis
An apoptotic ELISA kit (Roche Diagnostics Corp.,
Indianapolis, IN, USA) was used to quantitatively measure
cytoplasmic histone-associated DNA fragments (mononu-
cleosomes and oligonucleosomes) as previously reported
[27,28,30]. This enzyme immunoassay was performed ac-
cording to the manufacturer’s instructions.
Western blot analysis
Protein expression levels were determined by western
blot analysis as described previously [27,28,30,31]. Equalamounts of total cell lysates were boiled in Laemmli
SDS-sample buffer, resolved by SDS-PAGE, transferred
to nitrocellulose membrane (Bio-Rad Laboratories,
Hercules, CA, USA), and probed with the primary anti-
bodies described in the figure legends. After the blots
were incubated with horseradish peroxidase-labeled sec-
ondary antibody (Jackson ImmunoResearch Laborator-
ies, West Grove, PA, USA), the signals were detected
using the enhanced chemiluminescence reagents (GE
Healthcare Bio-Sciences Corp., Piscataway, NJ, USA).
Immunohistochemistry (IHC)
Five-micron-thick paraffin sections were deparaffinized,
antigens unmasked and immunohistochemically stained
for Ki-67 (Thermo Fisher Scientific; rabbit monoclonal
SP6; cat# RM-9106-SO; dilution 1:500 in Tris-buffered
saline and Tween 20 (TBST) + 1% BSA w/v), cleaved
caspase-3 (Cell Signaling Technology; rabbit polyclonal;
cat#: 9661, 1:1,000 in TBST + 1% BSA w/v), Survivin
(Epitomics, Burlingame, CA, USA; rabbit monoclonal
EP2880Y; cat# 2463; dilution 1:100 in TBST + 1% BSA
w/v), erbB2 (EMD Chemicals; mouse monoclonal 96G;
cat#OP14T; dilution 1:500 in TBST + 1% BSA w/v), and
erbB3 (Spring Bioscience, Pleasanton, CA, USA; rabbit
monoclonal SP71; cat# M3710; dilution 1:200 in TBST +
1% BSA w/v). The specificity of all antibodies has been
confirmed by both positive and negative controls. For
erbB2 and erbB3, SKBR3 cells were used as a positive con-
trol. For Survivin, the endometrial cancer tissues originat-
ing from ovary were used a positive control. For Ki-67 and
cleaved caspase-3, human tonsil tissues were used a posi-
tive control. For the negative controls, in addition to use
the same cells/tissues without addition of the primary
antibodies, we also performed the IHC assays using the
tissues or cell lines that are known to have no expression
of the antigens (Additional file 1).
Ki-67, cleaved caspase-3 and Survivin antigens were
revealed in pH 9.5 BORG solution (Biocare Medical,
Concord, CA) for 5 minutes at 125°C (22 psi; decloaking
chamber, Biocare). ErbB2 required modest retrieval in
10 mmol/L sodium citrate for 5 minutes at 125°C in the
decloaking chamber. ErbB3 required retrieval in Cell
Conditioner 1 (standard retrieval time, Ventana Medical
Systems, Tucson, AZ, USA). Immunodetection of Ki-67,
cleaved caspase-3 and erbB2 was performed on the
NexES stainer (Ventana) at an operating temperature of
37°C. Ki-67 and cleaved caspase-3 antibodies were incu-
bated for 32 minutes and detected with a modified I-VIEW
DAB detection kit (Ventana). The I-VIEW secondary anti-
body and enzyme were replaced with a species-specific
secondary antibody (biotinylated goat anti-rabbit; 1:75;
cat# 111-065-144; Jackson ImmunoResearch; 8 minutes)
and streptavidin-horseradish (SA-HRP; 1:50; cat# SA-5004;
DAKO Cytomation, Carpinteria, CA, USA; 8 minutes).
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the Rabbit ImmPress polymer detection system (Vector
Laboratories, Burlingame, CA, USA; cat# MP-7401).
ErbB2 was incubated for 32 minutes and detected with
the standard I-VIEW detection. ErbB3 was incubated
for 32 minutes and detected with a modified I-VIEW
DAB kit in which the secondary antibody was replaced
with Rabbit ImmPress (Vector Laboratories; cat# MP-
7401; 8 minutes at 37°C) and enzyme was replaced with
Rabbit ImmPress (diluted 1:1 in PBS, pH 7.6; 8 minutes at
37°C). Sections were sequentially blocked for 10 minutes
in 3% hydrogen peroxide (v/v) and 30 minutes in Rodent
Block M (Biocare; cat# RBM961), followed by primary
antibody incubation for 30 minutes and 30 minutes in
polymer. Antibody complexes were visualized with IP Flex
DAB (Biocare; cat# IPK5010 G80; 4.5%). All sections were
counterstained in Mayer’s hematoxylin for 2 minutes, nu-
clei blued in 1% ammonium hydroxide (v/v), dehydrated
in graded alcohols, cleared in xylene and coverglass-
mounted using synthetic resin.
Tumor xenograft model
Athymic nu/nu mice (Harlan Laboratories, Inc., Indianapolis,
IN, USA) were maintained in accordance with the Insti-
tutional Animal Care and Use Committee (IACUC)
procedures and guidelines approved by University of
Colorado Health Sciences Center Animal Care and Use
Committee. We suspended 8 × 106 BT474-HR20 cells in
100 μL of PBS mixed with 50% Matrigel (BD Biosciences)
and injected these subcutaneously into the flanks of 5-
week-old female mice. Tumor formation was assessed by
palpation and measured with fine calipers three times a
week. Tumor volume was calculated by the formula
shown below, where length was the longest axis and width
the measurement at a right angle to the length:
Volume = (Length × Width2)/2
This was followed by statistical analysis as we de-
scribed previously [32]. When tumors reached approxi-
mately 150 mm3 or 100 mm3, mice were randomly
assigned into four groups (n = 5): 1) control-group mice
received intraperitoneal (i.p.) injection of 100 μl PBS; 2)
mice received i.p. injection of paclitaxel (15 mg/kg or
7.5 mg/kg) in 100 μl PBS twice a week; 3) mice received
i.p. injection of MM-121 (10 mg/kg) in 100 μl PBS twice a
week, or 4) mice received i.p. injection of paclitaxel
(15 mg/kg or 7.5 mg/kg) and MM-121 (10 mg/kg) in
100 μl PBS twice a week. The animals’ health status was
monitored daily for weight loss or for signs of altered
motor ability while in their cages. At the end of study,
mice were euthanized according to the approved IACUC
protocol. Tumors from all animals were excised and em-
bedded in paraffin for IHC analyses.Statistics
Statistical analyses of the experimental data were per-
formed using either the two-sided t-test or analysis of
variance (ANOVA) for each time point followed by
post-hoc testing between groups. Significance was set
at a P-value <0.05. All statistical analyses were con-
ducted with the software StatView v5.1 from SAS Insti-
tute Inc., Cary, NC, USA.
Results
MM-121 overcomes paclitaxel resistance induced by co-
expression of erbB2 and erbB3 in breast cancer cells and
significantly enhances inhibitory activity of paclitaxel
To study whether inactivation of erbB3 signaling with
MM-121 may overcome paclitaxel resistance and facilitate
paclitaxel-mediated inhibitory activity against erbB2-
overexpressing breast cancer, the SKBR3.B3.1 and SKBR3.
B3.2 cells that show resistance to paclitaxel due to ec-
topic expression of erbB3 in SKBR3 cells [27] were used
to investigate inhibitory effects of MM-121 on erbB3
signaling and enhancement of paclitaxel-mediated anti-
proliferative/anti-survival effects. Although SKBR3.B3.1
and SKBR3.B3.2 cell lines were less sensitive to pacli-
taxel than the parental SKBR3 and vector control
SKBR3.neo1 cell lines [27], (this lower responsiveness
was further confirmed in the current studies shown in
Additional file 2), paclitaxel was still able to inhibit pro-
liferative/survival of SKBR3.neo1, SKBR3.B3.1, and
SKBR3.B3.2 cells in a dose-dependent manner (Figure 1A).
Importantly, the presence of MM-121 significantly en-
hanced paclitaxel-mediated inhibitory activity in all three
cell lines (Figure 1A). Western blot analyses showed that
treatment of SKBR3.neo1, SKBR3.B3.1, and SKBR3.B3.2
cell lines with MM-121 reduced the levels of phos-
phorylated erbB3 (P-erbB3) and phosphorylated erbB2
(P-erbB2) in a time-dependent manner (Figure 1B).
These data suggest that MM-121 mainly inhibits acti-
vation of erbB3, which is in agreement with other re-
ports [23,24]. Since erbB3 interacted with the erbB2
receptor to activate erbB2, it is understandable that in-
activation of erbB3 with MM-121 might disrupt the
heterodimerization of erbB2/erbB3 receptors, and thus
decrease the kinase activity of erbB2 (phosphorylation).
Furthermore, treatment with MM-121 gradually re-
duced the levels of phosphorylated Akt (P-Akt), but
had no significant effects on phosphorylated MAPK
(P-MAPK) (Figure 1B). These data are consistent with
our previous findings showing that the PI-3 K/Akt
pathway is the major downstream signaling mechanism
for erbB2/erbB3 interactions in breast cancer cell lines
[26,27]. Taken together, our data indicate that the anti-
erbB3 Ab MM-121 exhibits the potential to overcome
paclitaxel resistance and significantly enhances paclitaxel-
mediated anti-proliferative/anti-survival effects in erbB2-







































































0 2     4 8 10   16
Paclitaxel (nmol/L)
SKBR3.neo1
0     24    48   
Figure 1 MM-121 significantly enhances paclitaxel-mediated anti-proliferative/anti-survival effects on breast cancer cell lines with
expression of both erbB2 and erbB3. (A) SKBR3.neo1, SKBR3.B3.1, or SKBR3.B3.2 cells were plated onto 96-well plates and incubated at 37°C
with 5% CO2. After 24 h, the culture medium was replaced with 0.1 ml fresh medium containing 0.5% FBS or the same medium containing the
indicated concentrations of paclitaxel in the absence (paclitaxel) or presence (MM-121 + pac) of MM-121 (10 μg/ml) for another 72 h. The percent-
ages of surviving cells from each cell line relative to controls, defined as 100% survival, were determined by reduction of 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS). Bars represent SD. Data are representative of three independent
experiments. (B) The same cells were untreated or treated with MM-121 (10 μg/ml) for 24 or 48 h. Cells were collected and subjected to western blot
analyses of phosphorylated (P)-erbB2, erbB2, P-erbB3, erbB3, P-Akt, Akt, P-mitogen-activated protein kinase (P-MAPK), MAPK, or β-actin.
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high erbB3 expression, associated with its inhibition of the
erbB3/PI-3 K/Akt signaling.
MM-121 specifically downregulates Survivin in
paclitaxel-resistant breast cancer cell lines and
significantly enhances paclitaxel-induced apoptosis in
both sensitive and resistant cells
To study the molecular mechanism by which MM-121
overcomes paclitaxel resistance and increases paclitaxel-
mediated anti-proliferative/anti-survival effects in the
studied erbB2-overexpressing breast cancer cell lines, we
investigated whether MM-121 might enhance paclitaxel-
induced apoptosis. Because activation of erbB2/erbB3
signaling resulted in paclitaxel resistance via PI-3 K/Akt-
dependent upregulation of Survivin [27] and we showed
that MM-121 mainly inactivated Akt in all three SKBR3sublines (Figure 1B), we hypothesized that MM-121
might inhibit Survivin expression in both paclitaxel-
sensitive and -resistant breast cancer cells. Indeed, west-
ern blot analyses revealed that treatment of SKBR3.neo1,
SKBR3.B3.1, and SKBR3.B3.2 cell lines with MM-121 led
to decreased Survivin, but had no effects on the func-
tionally related proteins, such as Bcl-xL and Mcl-1, in a
time-dependent manner (Figure 2A). These data are
consistent with our previous studies indicating that the
erbB3 signaling specifically regulates Survivin expression
in erbB2-overexpressing breast cancer cells [27]. More-
over, although SKBR3.B3.1 and SKBR3.B3.2 cells were
less responsive than the parental SKBR3 and vector
control SKBR3.neo1 cells to paclitaxel-induced apop-
tosis, the addition of MM-121 significantly enhanced
paclitaxel-induced apoptosis in both paclitaxel-sensitive
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Figure 2 MM-121 specifically downregulates Survivin and
significantly enhances paclitaxel-induced apoptosis in
paclitaxel-sensitive and -resistant breast cancer cells. (A) SKBR3.
neo1, SKBR3.B3.1, or SKBR3.B3.2 cells were untreated, or treated with
MM-121 (10 μg/ml) for 24 or 48 h. Cells were collected and subjected
to western blot analyses of Survivin, Bcl-xL, Mcl-1, or β-actin. The
densitometry analyses of Survivin signals are shown underneath,
and the arbitrary numbers indicate the intensities of each cell line
relative to controls, defined as 1.0. (B and C) SKBR3 and SKBR3.
B3.1, or SKBR3.neo1 and SKBR3.B3.2 cells were untreated, or treated
with either MM-121 (10 μg/ml) or paclitaxel (3 nmol/L) alone, or
their combinations for 24 h. Cells were collected (samples of SKBR3
and SKBR3.B3.1 cells were run on one gel, and samples from SKBR3.
neo1 and SKBR3.B3.2 cells were run on another) and subjected to
western blot analyses of poly(ADP-ribose) polymerase (PARP: F-PARP,
full-length PARP; C-PARP, cleaved PARP), caspase-8 (F-Casp-8, full-length
caspase-8; C-Casp-8, cleaved caspase-8), caspase-3 (F-Casp-3, full-length
caspase-3; C-Casp-3, cleaved caspase-3), or β-actin (B); or a specific
apoptosis ELISA (C). Bars represent SD. *P <0.001 and **P <0.003 versus
single-agent treatment.
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and paclitaxel, as compared to either agent alone, gave
rise to a profound induction of cleaved PARP and acti-
vation of caspase-8 and −3 (Figure 2B), as well ashistone-associated DNA fragments (Figure 2C). Thus,
our studies demonstrate that MM-121 overcomes pacli-
taxel resistance and enhances paclitaxel-induced apop-
tosis in the studied erbB2-overexpressing breast cancer
cell lines via specific downregulation of Survivin.
Elevated expression of Survivin is observed in one
trastuzumab-resistant breast cancer cell line and shows
cross-resistance to paclitaxel that can be abrogated by
MM-121
We previously reported that the three RTKs, erbB2,
erbB3, and IGF-1R interacted with each other to form a
heterotrimeric complex, which activates the downstream
signaling, such as PI-3 K/Akt or MEK/MAPK pathways
and Src kinase in trastuzumab-resistant breast cancer cells
[28]. We explored whether the trastuzumab-resistant sub-
lines BT474-HR20 and SKBR3-pool2 might also have in-
creased expression of Survivin due to the activation of PI-
3 K/Akt signaling, and subsequently exhibit resistance to
paclitaxel-induced apoptosis. Compared to the parental
BT474 cells, the trastuzumab-resistant BT474-HR20 cells
expressed much higher levels of Survivin and had a
minor increase in Mcl-1. The expression levels of Bcl-
xL showed no difference between BT474 and BT474-
HR20 cells (Additional file 3: Figure S2A). Interestingly,
BT474-HR20 cells were significantly more resistant to
paclitaxel-mediated anti-proliferative/anti-survival ef-
fects than BT474 cells (Additional file 3: Figure S2B).
However, this phenomenon was not observed in another
pair of trastuzumab-sensitive SKBR3 and -resistant SKBR3-
pool2 cells, as we did not find a significant induction of
Survivin, Mcl-1, or Bcl-xL in SKBR3-pool2 cells (data not
shown). The difference might be due to the fact that
BT474-HR20 cells exhibited a dramatic activation of Akt as
compared to BT474 cells, whereas significant activation of
MAPK, but not Akt was discovered in SKBR3-pool2 cells
[28]. To study whether the enhanced expression of Survivin
in BT474-HR20 cells causally induced paclitaxel resistance,
two shRNA sequences (Survivin-S3 and -S5) were used
to specifically knock down Survivin (Figure 3A). Com-
pared to control shRNA, both Survivin-S3 and Survivin-
S5 significantly enhanced paclitaxel-induced apoptosis
evidenced by increased PARP cleavage, caspase-3 activa-
tion (Figure 3B), and an apoptotic ELISA (Figure 3C).
These data strongly suggest that the increased Survivin in
the studied trastuzumab-resistant cell line causally elicited
cross-resistance to paclitaxel. Because activation of the
erbB3 signaling played an important role in the develop-
ment of BT474-HR20 cells, we next studied whether
MM-121 might also reduce Survivin in BT474-HR20 cells
and therefore re-sensitize the cells to paclitaxel-mediated
inhibitory activity and apoptosis. We discovered that
MM-121 not only reduced the levels of P-erbB3, but also
specifically downregulated Survivin (not Bcl-xL and Mcl-1)
Paclitaxel
(8nmol/L)


















































Figure 3 Specific knockdown of Survivin expression with
shRNA significantly promotes paclitaxel-induced apoptosis in a
trastuzumab-resistant breast cancer cell line. BT474-HR20 cells
infected with lentivirus containing either control shRNA (ConshRNA) or
Survivin shRNA (Survivin-S3, Survivin-S5) were subjected to the following
experiments. (A) Western blot analyses of Survivin, Bcl-xL, Mcl-1, or
β-actin. (B and C) The cells were then untreated, or treated with
paclitaxel (8 nmol/L) for 24 h. The cells were collected and subjected
to (B) western blot analyses of poly(ADP-ribose) polymerase (PARP),
cleaved caspase-3, or β-actin; or to (C) apoptosis ELISA. Bars represent SD.
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findings in the SKBR3 sublines (Figures 1B and 2A).
More importantly, MM-121 significantly enhanced both
paclitaxel-mediated anti-proliferative/anti-survival ef-
fects (Figure 4B) and apoptosis (Figure 4D), and facili-
tated paclitaxel-induced PARP cleavage and activation
of caspase-8 and −3 (Figure 4C) in BT474-HR20 cells.
Collectively, our data demonstrate that MM-121 wasalso able to abrogate paclitaxel resistance-induced by
elevated expression of Survivin in the trastuzumab-
resistant breast cancer cells.
The combinations of MM-121 and paclitaxel at a lower
dose significantly inhibit tumor growth in a xenograft
model established from the trastuzumab-resistant
BT474-HR20 breast cancer cells
To further explore whether MM-121 holds potential to
enhance the efficacy of paclitaxel in breast cancer treat-
ment, we took advantage of a tumor xenograft model
established from the trastuzumab-resistant BT474-HR20
cells. For the first set of in vivo experiments, when larger
tumors (approximately 250 mm3) were established, the
tumor-bearing mice were treated with either PBS (con-
trol), or MM-121 (10 mg/kg) or paclitaxel (15 mg/kg)
alone, or with the combinations of MM-121 and pacli-
taxel. All treatments were carried out by i.p. injection
twice a week. We discovered that whereas treatment
with MM-121 had no effects on tumor growth, pacli-
taxel at a dose of 15 mg/kg significantly inhibited tumor
growth in this model. Similar inhibitory effects on tumor
growth were observed with the combinations of MM-
121 and paclitaxel (15 mg/kg) (Additional file 4). For the
second set of in vivo experiments using smaller tumors
(approximately 100 mm3), a lower dose of paclitaxel was
used to treat the tumor-bearing mice. Although treat-
ment with either MM-121 or paclitaxel (7.5 mg/kg)
alone had little effect on tumor growth, their combina-
tions significantly inhibited tumor growth in this xenograft
model (Figure 5A). These data suggest that MM-121 en-
hances low-dose paclitaxel-mediated antitumor activity
against erbB2-overexpressing breast cancer in this in vivo
mouse model. After 3-week (twice/week) treatments, the
remaining tumors obtained from the second study were
subjected to histology and IHC analyses. Our data re-
vealed that treatment with either MM-121 or paclitaxel
(7.5 mg/kg) had no significant effects on tumor cell
morphology, tumor mass architecture, and the expression
of erbB2/erbB3 receptors (Figure 5B). In contrast, smaller
tumor mass and bigger empty spaces among tumor cells
were found with the combinatorial treatment. Nonethe-
less, the remaining tumor cells expressed similar levels of
erbB2 and erbB3 (Figure 5B).
MM-121 in combination with paclitaxel significantly
inhibits tumor cell proliferation, reduces expression of
Survivin, and promotes more cells undergoing apoptosis
in the in vivo mouse model
Our in vitro studies showed that MM-121 significantly
enhanced paclitaxel-mediated anti-proliferative/anti-sur-
vival effects and facilitated paclitaxel-induced apoptosis
in BT474-HR20 cells (Figure 4). We wondered whether
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Figure 4 MM-121 specifically downregulates Survivin and significantly enhances paclitaxel-induced anti-proliferative/anti-survival
effects and apoptosis in a trastuzumab-resistant breast cancer cell line. (A) BT474-HR20 cells were untreated, or treated with MM-121
(10 μg/ml) for 24 or 48 h. Cells were collected and subjected to western blot analyses of P-erbB3, erbB3, Survivin, Bcl-xL, Mcl-1, or β-actin. The
densitometry analyses of Survivin signals are shown underneath, and the arbitrary numbers indicate the intensities of each sample relative to
control, defined as 1.0. (B) BT474-HR20 cells were plated onto 96-well plates and incubated at 37°C with 5% CO2. After 24 h, the culture medium
was replaced with 0.1 ml fresh medium containing 0.5% FBS or the same medium containing the indicated concentrations of paclitaxel in the
absence (paclitaxel) or presence (MM-121 + pac) of MM-121 (10 μg/ml) for another 72 h. The percentages of surviving cells from each cell line
relative to controls, defined as 100% survival, were determined by reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium, inner salt (MTS). Bars represent SD. Data are representative of three independent experiments. (C and D) BT474-HR20 cells
were untreated, or treated with either MM-121 (10 μg/ml) or paclitaxel (8 nmol/L) alone, or their combinations for 24 h. Cells were collected and
subjected to western blot analyses of poly(ADP-ribose) polymerase (PARP), caspase-8, caspase-3, or β-actin (C); or a specific apoptosis ELISA
(D). Bars represent SD. *P <0.0002 versus single-agent treatment.
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The tumor tissues obtained from the animal studies de-
scribed above were further used for IHC studies on the
classic cell proliferative marker, Ki-67, and the apoptosis
marker, cleaved caspase-3, as well as the expression of
Survivin. The mice treated with MM-121 alone did not
have alteration in the number of tumor cells with posi-
tive staining for Ki-67, Survivin, and cleaved caspase-3
compared to the control mice (Figure 6A). Although
paclitaxel (7.5 mg/kg) alone had no effects on Ki-67
staining, it did significantly decrease the expression of
Survivin and induce caspase-3 cleavage in the tumor
cells (Figure 6A and B). More importantly, the combina-
torial treatments exhibited a significant reduction in the
number of tumor cells with positive staining for Ki-67, a
striking downregulation of Survivin, and a dramatic
increase of the tumor cells with cleaved caspase-3(Figure 6). These data indicate that MM-121 enhances
paclitaxel antitumor activity against erbB2-overexpressing
breast cancer via simultaneous inhibition of tumor cell
proliferation and induction of apoptosis in vivo.
Discussion
The erbB3 receptor has long been considered as an
inactive pseudokinase [10,11], although a recent study
suggests that erbB3 has weak kinase activity that can
trans-autophosphorylate its intracellular region [12]. In
order to fully transduce cell signaling, however, erbB3
has to be phosphorylated by its interactive partners; of
these, erbB2 is the most important one [33]. It has been
well-documented that activation of the erbB3 signaling
plays a pivotal role in the development of erbB2-
overexpressing breast cancer [13,14]. Although a num-
ber of strategies targeting erbB2 are being used in the










































Figure 5 MM-121 in combination with low-dose paclitaxel
significantly inhibits in vivo tumor growth of trastuzumab-
resistant breast cancer cells in a murine model. BT474-HR20 cells
were subcutaneously injected into nude mice to establish tumor
xenografts. The tumor-bearing mice (n = 5) received intraperitoneal
injections of either PBS, or MM-121 (10 mg/kg), or paclitaxel
(7.5 mg/kg) alone, or both MM-121 and paclitaxel as described in
Methods. After six treatments the mice were euthanized at day 36
post injection of tumor cells, and all tumors were excised for
histology and IHC analysis. (A) The graphs show the tumor growth
curves. Bars represent SD. *P <0.04 versus control or MM-121;
**P <0.05 versus MM-121 and P <0.005 versus paclitaxel; ***P <0.04
versus paclitaxel; ****P <0.05 versus control, P <0.008 versus MM-121,
and P <0.02 versus paclitaxel; *****P = 0.005 versus control, P <0.004
versus MM-121, and P = 0.0006 versus paclitaxel. (B) Data show the
representative tumors with H&E staining and IHC analysis of erbB2
and erbB3 receptors.
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http://breast-cancer-research.com/content/15/5/R101clinic [34], no erbB3-targeted therapy has been approved
for cancer treatment. MM-121 is an erbB3-blocking Ab
that is being actively investigated in clinical trials of can-
cer patients with solid tumors, such as advanced non-
small cell lung cancer, colorectal cancer, squamous cell
head and neck cancer, and platinum resistant/refractory
ovarian cancer [35]. In breast cancer, the therapeuticpotential of MM-121 is being tested in patients with es-
trogen receptor- and/or progesterone receptor-positive
and erbB2-negative breast cancers in combination with
the aromatase inhibitor exemestane, and in patients with
triple-negative or erbB2-negative breast cancers in com-
bination with paclitaxel. To date, no study has been ini-
tiated to test the activity of MM-121 in breast cancer
patients with erbB2-overexpressing tumors, including
those resistant to paclitaxel. Here we provide experimen-
tal evidence indicating that MM-121 inactivates erbB3
(Figures 1B and 4A), significantly enhances paclitaxel-
induced anti-proliferative/anti-survival effects (Figures 1A,
4B, 5A, and 6), and apoptosis (Figures 2B, 2C, 4C, 4D,
and 6) in erbB2-overexpressing breast cancer cells with
either medium (SKBR3, SKBR3.neo1, and BT474-HR20)
or high erbB3 (SKBR3.B3.1 and SKBR3.B3.2) expression.
Our data suggest that MM-121 is efficacious in all erbB2-
overexpressing breast cancer cell lines tested. We believe
that MM-121 will exhibit therapeutic potential in all
erbB2-positive breast cancer patients (not only those with
strong erbB3-expressing tumors) as long as the tumors
show active erbB3 signaling.
The concentrations of paclitaxel used in the in vitro
studies (0 to 16 nmol/L or 0 to 32 nmol/L) are much
lower than the average steady-state plasma concentra-
tions of paclitaxel (300 to 800 nmol/L) found in patients
[36,37]. This difference may be explained by the two
very distinct systems. In the 2-dimensional cell culture
condition, paclitaxel should easily get into the tumor
cells which grow as a monolayer. However, due to the
complexity of the human body, some substances in the
circulation may attenuate the efficacy of paclitaxel. The
presence of fibroblast, microphage, immune cells and
others in the tumor mass may block or decrease the
drug’s entry into the tumor cells. In addition, because of
the heterogeneicity of tumors and their 3-dimensional
architecture, drug uptake varies in tumor cells. Thus, the
steady-state plasma concentration of paclitaxel may not
reflect the drug concentration inside the tumor cells.
The data obtained from our animal studies provide fur-
ther support of this point. It has been reported that ad-
ministration of 10 mg/kg paclitaxel to mice gives rise to
a peak plasma concentration of approximately 3 μmol/L,
which gradually and near-linearly declines to 0 at 16 h
[38]. This peak concentration of paclitaxel is much
higher than that we used in our cell culture studies.
However, in the in vivo studies, although administration
of 15 mg/kg paclitaxel to mice had significant inhibitory
effects on tumor growth (Additional file 4), we found
no such effect when paclitaxel was used at 7.5 mg/kg
(Figure 5A). Thus, both our in vitro and in vivo data
seem to indicate that the ability of MM-121 to enhance
the therapeutic efficacy of paclitaxel against erbB2-











































































































Figure 6 The combination of MM-121 and paclitaxel significantly inhibits tumor cell proliferation, reduces expression of Survivin, and
induces apoptosis in an in vivo mouse model. The tumors obtained from the animal studies described above were evaluated by
immunohistochemical (IHC) analysis of Ki-67, Survivin, and cleaved caspase-3. (A) Data show the representative images of the immunostainging
of Ki-67, Survivin, and cleaved caspase-3. (B) The IHC slides were observed by two independent personnel. The tumor cells with positive staining
of Ki-67, Survivin, or cleaved caspase-3 were counted from three randomly selected areas in each slide. The three areas were first identified by
scanning the entire slide at × 100 magnification, and then the positive-stained cells were counted at × 200 magnification using an Olympus BX40
microscope. The bar graphs show the average of positive staining cells in each field. Bars represent SD. *P <0.002 versus control or MM-121.
**P <0.001 versus control or single-agent treatment.
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http://breast-cancer-research.com/content/15/5/R101ineffective doses of paclitaxel. Although a recent report
shows that as a single agent, neoadjuvant treatment
with paclitaxel induces tumor response in 92% of pa-
tients with erbB2-overexpressing breast cancer [39],
our findings suggest that the presence of MM-121 may
convert the tumors from non-responsive to responsive
to the lower doses of paclitaxel with less side effects,
and therefore merit translational implications in the
clinic.
We have reported that the underlying mechanism that
elevated expression of erbB3 results in paclitaxel resist-
ance in erbB2-overexpressing breast cancer cells is attrib-
uted to PI-3 K/Akt-dependent upregulation of Survivin[27]. Numerous studies indicate that Survivin functions as
a critical inhibitor of apoptosis to promote cell survival
and proliferation, and regulates mitosis during cell cycle
progression [40]. Survivin is selectively expressed in a var-
iety of human malignancies and its overexpression posi-
tively correlates with poor prognosis, tumor recurrence
and therapeutic resistance [40]. A number of different
strategies targeting Survivin, including antisense oligo-
nucleotide and pharmacological inhibitors have been de-
veloped and are currently under clinical trials for cancer
treatment [40-42]. Our data showed that inactivation of
erbB3 signaling with MM-121 specifically downregulated
Survivin in our in vitro models, and significantly enhanced
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wise resistant breast cancer cells (Figures 1 and 2). In our
mouse model, although treatment with MM-121 alone
had no significant effects on Survivin expression, MM-121
did dramatically downregulate Survivin when combined
with paclitaxel (Figure 6). It is possible that MM-121 at
the dose we used only partially inhibits the PI-3 K/Akt sig-
naling in vivo, and the inactivation of Akt to such an ex-
tent alone could not significantly alter the expression of
Survivin. Alternatively, other signaling pathways may also
be critical to control Survivin expression in the in vivo cir-
cumstance. A marked reduction of Survivin was only ob-
served with the combinatorial treatment. In addition, we
have found that hMP-RM-1, a humanized version of the
anti-erbB3 Ab MP-RM-1 [43], exhibited similar in vitro
activity to specifically downregulate Survivin in erbB2-
overexpressing breast cancer cells (data not shown). Thus,
inhibition of erbB3 with blocking Ab may be a novel strat-
egy to target Survivin for cancer treatment. As MP-RM-1
inhibits both ligand-dependent and -independent activa-
tion of erbB3 [43], we speculate that hMP-RM-1 might
exert more potent antitumor activity than MM-121
against erbB2-overexpressing breast cancer. More detailed
studies are needed to confirm our hypothesis.
Elevated expression of Survivin was also observed in the
trastuzumab-resistant subline BT474-HR20 and causally
led the cells resistant to paclitaxel-induced apoptosis
(Additional files 3 and 4). However, we did not find Survi-
vin upregulation in another trastuzumab-resistant subline
SKBR3-pool2. These data suggest that elevated expression
of Survivin may cause cross-resistance to paclitaxel treat-
ment in some trastuzumab-resistant breast cancers. We
believe that profound activation of PI-3 K/Akt signaling,
which we observed in BT474-HR20, but not in SKBR3-
pool2 cells [28], is the major mechanism contributing to
the upregulation of Survivin. At this moment, it remains
unclear whether activation of the PI-3 K/Akt signaling by
any means, such as PIK3CA mutation or phosphatase and
tensin homolog (PTEN) deletion in addition to erbB2/
erbB3 receptors, would also enhance expression of Survi-
vin in breast cancer cells. The interesting phenomenon of
Survivin-mediated cross-resistance to paclitaxel and tras-
tuzumab warrants further investigation.
Activation of the PI-3 K/Akt signaling has been identi-
fied as the major determinant of trastuzumab resistance
[29]. In addition to inducing paclitaxel resistance, the
erbB2/erbB3/PI-3 K/Akt signaling also results in resist-
ance to hormonal therapy [44] and other chemotherapy
[45] in breast cancer treatment. Because MM-121
mainly inhibits activation of erbB3 and Akt in erbB2-
overexpressing breast cancer cells, it is conceivable to
hypothesize that MM-121 may abrogate erbB3 signaling-
mediated therapeutic resistance to tamoxifen, trastuzumab,
and other chemotherapeutic agents, such as doxorubicin.By taking advantage of the trastuzumab-resistant breast
cancer model (BT474-HR20 and SKBR3-pool2), we have
discovered that MM-121 is able to overcome trastuzumab
resistance and significantly enhance trastuzumab-induced
growth inhibition and/or apoptosis in vitro and in vivo
(submitted separately).Conclusions
We demonstrate that targeting of erbB3 with the blocking
Ab MM-121 significantly enhances paclitaxel antitumor
activity against erbB2-overexpressing breast cancer cells in
our in vitro and in vivo models. In those models, MM-121
is active to overcome the resistance to paclitaxel, and such
a capability of MM-121 may be restricted to the ineffective
doses of paclitaxel. Mechanistically, MM-121 inhibits the
PI-3 K/Akt signaling, downregulates Survivin, and subse-
quently enhances paclitaxel-mediated cytotoxicity and
apoptosis in vitro. The combinations of MM-121 and pac-
litaxel significantly inhibit tumor cell proliferation, reduce
expression of Survivin, and induce apoptosis in vivo. Our
data support further studies to explore the therapeutic po-
tential of MM-121 in combination with paclitaxel in
breast cancer patients with erbB2-overexpressing tumors.Additional files
Additional file 1: Figure S4. Evaluation of specificity of the antibodies
used in the immunohistochemistry (IHC) studies. (A) The anti-Ki67 antibody
was tested using the tumor xenografts established by the human breast
cancer cell line MDA-MB-231 in a nude mouse. The picture was taken at
×100 magnification by an Olympus BX40 microscope. Both positive-staining
MDA-MB-231 tumor cells and negative staining of the adjacent mouse
lymphocytes are indicated as (+) and (-), respectively.
(B) The human breast cancer cell line MCF-7, which has no erbB2
expression, and SKBR3, which is a well-known erbB2-overexpressing breast
cancer cell line, were used to assess the anti-erbB2 antibody. Both cell lines
under normal culture condition were collected, paraffin-embedded, and
then followed by the standard procedure of IHC analysis. The pictures were
taken at ×200 magnification. (C) Tumor sections obtained from the
BT474-HR20 tumor xenografts described in the current studies (in the
animals without treatment) were used to evaluate the antibodies against
erbB3, Survivin, and cleaved caspase-3. All pictures were taken at ×200
magnification. Wheareas the BT474-HR20 tumor cells showed positive
staining of erbB3 (+), Survivin (+), and rare cleaved caspase-3 (+), the
fibroblast cells (likely from the host) stained negative for erbB3 (-) and the
adjacent mouse lymphocytes stained negative for Survivin (-). The majority
of the BT474-HR20 tumor cells were negative-stained for cleaved caspase-3
(-), because the animals received no treatment.
Additional file 2: Figure S1. SKBR3.B3.1 and SKBR3.B3.2 cell lines are
less responsive to paclitaxel-mediated anti-proliferative/anti-survival
effects than SKBR3.neo1 cells. SKBR3.neo1, SKBR3.B3.1, or SKBR3.B3.2 cells
were plated onto 96-well plates and incubated at 37°C with 5% CO2.
After 24 h, the culture medium was replaced with 0.1 ml fresh medium
containing 0.5% FBS or the same medium containing the indicated
concentrations of paclitaxel for another 72 h. The percentages of
surviving cells from each cell line relative to controls, defined as 100%
survival, were determined by reduction of 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
(MTS). Bars represent SD. Data are representative of three independent
experiments.
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http://breast-cancer-research.com/content/15/5/R101Additional file 3: Figure S2. The trastuzumab-resistant BT474-HR20
cells have elevated expression of Survivin and are significantly more
resistant to paclitaxel-mediated anti-proliferative/anti-survival effects than
the parental BT474 cells. (A) BT474 and its trastuzumab-resistant subline
BT474-HR20 cells in normal culture condition were collected and
subjected to western blot analyses of Survivin, Bcl-xL, Mcl-1, or β-actin.
(B) BT474 or BT474-HR20 cells were plated onto 96-well plates and
incubated at 37°C with 5% CO2. After 24 h, the culture medium was
replaced with 0.1 ml fresh medium containing 0.5% FBS or the same
medium containing the indicated concentrations of paclitaxel for another
72 h. The percentages of surviving cells from each cell line relative to
controls, defined as 100% survival, were determined by reduction of
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt (MTS). Bars represent SD. Data are representative
of three independent experiments.
Additional file 4: Figure S3. Combinations of MM-121 and high-dose
paclitaxel exhibit similar activity to high-dose paclitaxel alone to inhibit
tumor growth of trastuzumab-resistant breast cancer cells in vivo.
BT474-HR20 thyc=5?> cells were subcutaneously injected into nude mice
to establish tumor xenografts. The tumor-bearing mice (n = 5) received
intraperitoneal injections of either PBS, or MM-121 (10 mg/kg), or paclitaxel
(15 mg/kg) alone, or both MM-121 and paclitaxel as described in Methods.
After four treatments, the mice were euthanized at day 45 post inoculation of
tumor cells. The graphs show the tumor growth curves. Bars represent SD.
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